Western Union Foundation Announces New Partnerships to Advance Vaccine Education & Workforce Training in Q1/2021
8.4.2021 15:00:00 EEST | Business Wire | Press release
The Western Union Foundation today announced its first-quarter 2021 programs, investing more than USD 1.25 million to mobilize youth to access jobs in the healthcare industry, assisting with COVID-19 vaccine education and distribution, and to enable economic recovery through workforce training. This investment furthers the Western Union Foundation’s Opportunity Beyond Borders three-year USD 15 million commitment to provide migrant and young adults with resources to gain sustainable employment and provide relief and preparedness for crises.
“The Western Union Foundation recognizes that this moment—as the global pandemic recovery effort begins in earnest—is a crucial one for the communities we serve,” said Foundation Executive Director Elizabeth Roscoe. “We are determined to do everything we can to keep people who are already on the margins from falling farther behind because they lack access to vaccines or opportunities to participate in the formal labor markets as economies progress toward recovery.”
In 2020, the first full year of Opportunity Beyond Borders, the Western Union Foundation invested more than USD 6 million to help 200,000 people in 33 countries, as detailed in its 2020 Global Impact Report.
COVID-19 vaccine education, preparedness, and distribution programs
Research has shown a large portion of the population in many low-income countries is hesitant to get the vaccine, often due to lack of education about the vaccine and logistical challenges to reach vaccine centers. The Aspen Institute and International Medical Corps will receive funds from the Western Union Foundation to address these challenges.
In Kenya and India, the Aspen Institute will partner with leading community-based organizations to support vaccine education and distribution efforts by skilling youth and women in the community in vaccine awareness, preparedness and access.
In the Philippines, the International Medical Corps program will address vaccine hesitancy by driving awareness and coordinating transportation for vulnerable populations to vaccine centers.
In Pakistan, host to the third-largest number of refugees in the world, International Medical Corps will train volunteers in refugee villages to raise vaccine awareness and promote health and hygiene best practices.
Western Union and the Foundation are further enabling vaccine adoption by donating funds on behalf of each vaccinated Western Union employee and allowing employees to donate directly to the cause. This program will provide up to $350K to help inoculate thousands more in rural communities.
Workforce training for entrepreneurship and career pathways
In addition to the COVID-19 community resilience programs, the Foundation’s first-quarter investment aims to enable economic recovery for migrant and refugee communities affected by last year’s lockdowns. The following are a few of the programs:
In Mexico, the Whitaker Peace & Development Initiative will scale entrepreneurship programs by training young business leaders and incubating micro-businesses that provide essential services and products to their local communities.
In Jordan and Lebanon, the Kiron Open Higher Education program will work with the most vulnerable populations residing in refugee encampments and will offer skill-building opportunities to prepare individuals for and give access to career pathways.
In Jordan and Palestine, Education for Employment will launch a research study about relevant jobs post-COVID-19 and provide customized training to business owners, with the majority female, helping them adapt and grow their businesses in response to the effects of COVID-19.
To learn more about the impact the Western Union Foundation has made to people and partners over the past year, check out the stories of impact on their newly launched website.
About the Western Union Foundation
The Western Union Foundation believes that education is the surest pathway to economic opportunity. After 20 years of impact, we continue to deliver on our mission with Opportunity Beyond Borders, focused on empowering forcibly displaced and marginalized youth with the training and education needed to succeed in today’s technology-driven global economy. The Foundation also provides funding for humanitarian efforts for communities in crisis and disaster, one key reason for forced migration. To date, we have funded more than $131 million for projects and scholarships. The Western Union Foundation is a separate, tax-exempt 501(c)(3) charitable corporation and receives support from The Western Union Company, its employees, agents, and business partners. Contributions to the Foundation are tax-deductible for U.S. income tax purposes. To learn more, visit www.westernunionfoundation.org or follow us on Twitter @TheWUFoundation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005454/en/
Contact information
For further information please contact:
Western Union Global Communications; Pia De Lima; Pia.DeLima@wu.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
